# Endovascular treatment of true visceral artery aneurysms: a decade of experience and key outcomes from a high-volume single center

**Authors:** Laura Maria Cacioppa, Pietro Boscarato, Tommaso Valeri, Francesco Mariotti, Alessandra Bruno, Nicolò Rossini, Giangabriele Francavilla, Alice Aste, Olisea Di Lello, Marzia Rosati, Alessandro Felicioli, Vincenzo Vento, Emanuele Gatta, Laura Giantomassi, Enrico Paci, Roberto Candelari, Chiara Floridi

PMC · DOI: 10.1186/s42155-026-00664-0 · CVIR Endovascular · 2026-02-28

## TL;DR

This study shows that endovascular treatment is safe and effective for true visceral artery aneurysms, with high success and survival rates.

## Contribution

The paper presents a large, homogeneous dataset of true visceral artery aneurysms treated endovascularly at a single center over a decade.

## Key findings

- Endovascular treatment achieved 100% technical success with no perioperative deaths.
- Long-term survival was 89.4%, with low rates of complications and reintervention.
- Aneurysm sac reperfusion occurred in 8.2% of cases.

## Abstract

Endovascular approach has emerged as the first-choice treatment of visceral artery aneurysms (VAAs). However, most published series include heterogeneous populations combining true aneurysms and pseudoaneurysms. Our single-center retrospective study aimed to evaluate a large and homogenous series of true VAAs treated endovascularly. Demographic, clinical and procedural details of patients with VAAs treated at our Interventional Radiology unit from January 2014 to January 2025 were collected in a dedicated database. Intraprocedural and perioperative outcomes included technical success, complications, mortality and need for reintervention. At long-term follow-up, overall survival, aneurysm-related complications, freedom from reintervention, and aneurysmal sac reperfusion were evaluated.

Ninety-four consecutive patients (41 men; median age: 67.3 years; range 29–98 years) with 97 VAAs were included in the study. VAAs had a median diameter of 2.93 cm (range 6–9.2 cm). Treatment strategies included sac packing in 45 VAAs, sandwich technique in 35, covered stent placement in 13, afferent artery occlusion in 5 and stent-assisted coiling in 4 cases. Technical success rate was 100% with no perioperative deaths. Perioperative major complication and reintervention rates were 5.2% and 2.1%, respectively. At a mean follow-up of 44.7 ± 28.9 months, overall survival, freedom from aneurysm-related complications, and freedom from reintervention were 89.4%, 92.8%, and 93.8%, respectively. Aneurysm sac reperfusion was observed in 8(8.2%) cases. No aneurysm-related deaths occurred.

Endovascular approach is a safe and effective first-line option in patients with true VAAs, with notable results in terms of complication and freedom from reintervention rates and an excellent long-term overall survival.

## Full-text entities

- **Diseases:** type 2 diabetes mellitus (MESH:D003924), Gastric, (MESH:D013272), coronary artery disease (MESH:D003324), hypersensitivity (MESH:D004342), pain or compression symptoms (MESH:C538101), splenic (MESH:D013158), thrombosis (MESH:D013927), intra-abdominal aneurysms (MESH:D017544), portal hypertension (MESH:D006975), atherosclerotic (MESH:D050197), afferent artery occlusion (MESH:D001157), hypertension (MESH:D006973), connective tissue disorders (MESH:D003240), death (MESH:D003643), coronavirus disease 2019 (MESH:D000086382), pancreaticoduodenal and gastroduodenal aneurysms (MESH:D010437), infection (MESH:D007239), nausea (MESH:D009325), bleeding (MESH:D006470), acute respiratory failure (MESH:D012131), pleural effusion (MESH:D010996), pneumonia (MESH:D011014), aneurysm rupture (MESH:D017542), Ehlers-Danlos and Marfan syndromes (MESH:D008382), COPD (MESH:D029424), SMA aneurysm (MESH:D013478), ischemia (MESH:D007511), vomiting (MESH:D014839), hematoma (MESH:D006406), fibromuscular dysplasia (MESH:D005352), True visceral artery aneurysms (MESH:D002532), trauma (MESH:D014947), arterial vasculitis (MESH:D014657), aortic, iliac, femoral, or popliteal aneurysms (MESH:D017543), flank pain (MESH:D021501), pain (MESH:D010146), dyslipidemia (MESH:D050171), Takayasu arteritis (MESH:D013625), hematuria (MESH:D006417), pseudoaneurysm (MESH:D017541), rupture (MESH:D012421), vascular lesions (MESH:D014652), cerebral ischemia (MESH:D002545), Aneurysm (MESH:D000783), endoleaks (MESH:D057867), celiac trunk occlusion (MESH:D000074742), pancreatitis (MESH:D010195), aortic aneurysm (MESH:D001014), popliteal artery aneurysm (MESH:D000094622), splenic artery rupture (MESH:D013161), abdominal pain (MESH:D015746)
- **Chemicals:** heparin (MESH:D006493), Onyx  18-34 (-), platinum (MESH:D010984)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950147/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950147/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950147/full.md

---
Source: https://tomesphere.com/paper/PMC12950147